The aforementioned research indicates that oxaliplatin and the CDC7 inhibitor XL413 may be efficient in the treatment of liver, ovarian, and colon cancers; however, these studies are still in the preclinical stage, and additional clinical trials are required to confirm their safety and effectiveness. The gene discussed is CDC7; the disease is malignant colon neoplasm.